1. Jon Holmes

    0 Comments Leave a Comment

    76-90 of 102 « 1 2 3 4 5 6 7 »
    1. Mentioned In 102 Articles

    2. OCT technology development: Where are we now? A commercial perspective

      The field of optical coherence tomography (OCT) has grown enormously since its inception in 1991 at MIT, encompassing many areas of imaging research. Improvements in the optical technology used in OCT systems, and in the design of the OCT interferometers and probes, has resulted in steadily improving image quality and more practical probe designs. Successful commercial application of OCT occurred first in retina imaging, and many further applications now appear ...
      Read Full Article
    3. 76-90 of 102 « 1 2 3 4 5 6 7 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Jon Holmes

    Jon Holmes

    Jon D. Holmes is Founder & CTO of Michelson Diagnostics.

  3. Quotes

    1. Obtaining the Category III CPT code for OCT of the skin is an important step towards our goal of obtaining reimbursement and coverage, and we welcome the new codes that can be used by clinicians to record their clinical use of VivoSight OCT in their practice.
      In Michelson Diagnostics Secures CPT codes for Optical Coherence Tomography Imaging of Skin
    2. Jon Holmes, Co-Founder, Michelson Diagnostics, added: “delighted that Andy has joined the team at Michelson as CEO. Our ability to attract a CEO with such impressive credentials is a testament both to the team’s achievements to date and to the potential commercial opportunity of the VivoSight OCT system in non-melanoma skin cancer. With Andy now on board to spearhead our commercial growth, I look forward to driving the VivoSight OCT technology development and clinical validation into other clinical applications where we believe it can make a significant impact on patient diagnosis and treatment monitoring.
      In Andy Hill Appointed Chief Executive Officer of Michelson Diagnostics
    3. Our VivoSight OCT scanner is already proving popular with Dermatologists who are keen to deliver the best possible care to their non-melanoma skin cancer patients, and based on this initial feedback I am sure that the new improved probe with Micro-Camera will further accelerate the adoption of VivoSight OCT as a standard tool for the practising Dermatologist.
      In Michelson Diagnostics launches new improved version of VivoSight OCT scanner with Micro-Camera to aid skin cancer diagnosis
    4. We are delighted to be working with Dr Guitera and the Melanoma Institute of Australia. She is one of the top ten world experts in her field. We believe that our VivoSight system is the future of tumour diagnosis and monitoring and we looking forward to reporting the results in due course.
      In New study on non-invasive diagnosis of non-melanoma skin cancer with Melanoma Institute of Australia
    5. The positive results from our study clearly demonstrate the clinical benefits of using our VivoSight OCT system in the diagnosis and monitoring of basal cell carcinoma. We believe that VivoSight has the potential to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect the skin, and in particular non-melanoma skin cancers. We look forward to releasing the full data in due course.
      In Positive top line results from clinical trial for diagnosis of basal cell carcinoma using VivoSight OCT
    6. "We look forward to sharing the preliminary results from this important clinical study. It will hopefully provide level 1 evidence for the first time of the diagnostic value of OCT in dermatology and specifically its use in the detection of non-melanoma skin cancers such as basal cell carcinoma.”
      In Michelson Diagnostics announces completion of data collection in Vivosight OCT trial for BCC diagnosis
    7. We look forward to sharing the preliminary results from this important clinical study.
      In Michelson Diagnostics announces completion of data collection in Vivosight OCT trial for BCC diagnosis
    8. At Michelson Diagnostics, we strive to provide clinicians with cutting edge technology to enable accurate diagnosis of skin conditions. The additional functionality of this software places our VivoSight system at the forefront of dermatology diagnosis, reducing the need for biopsy and facilitating improved patient outcomes.
      In Michelson Diagnostics to launch enhanced software for VivoSight OCT scanner
    9. "We evaluated many available swept laser products when selecting a supplier for our new Vivosight system...We found Axsun to be the ideal company with whom to partner, offering the best platform of performance, value and volume manufacturing capability.
      In Axsun Technologies Announces Volume Purchase Order for Swept Laser Engines from Michelson Diagnostics Ltd.
    10. We are delighted to be the lead partner in the ADVANCE project. We believe this will be a significant development in the non-invasive diagnosis and monitoring of diseases and conditions that affect the skin. The capability to provide images of fine blood vessels in skin is likely to have many other clinical applications, such as monitoring treatment of inflammatory diseases and wound healing.
      In Michelson Diagnostics targets malignant melanoma using OCT imaging with €2.3M EU funding
  4. Quotes about Jon Holmes

    1. Jon Holmes, Chief Executive Officer of Michelson Diagnostics, commented
      In Michelson Diagnostics Announces £1.98 Million Financing
    2. Jon Holmes, Co-Founder, Michelson Diagnostics, added: “delighted that Andy has joined the team at Michelson as CEO. Our ability to attract a CEO with such impressive credentials is a testament both to the team’s achievements to date and to the potential commercial opportunity of the VivoSight OCT system in non-melanoma skin cancer. With Andy now on board to spearhead our commercial growth, I look forward to driving the VivoSight OCT technology development and clinical validation into other clinical applications where we believe it can make a significant impact on patient diagnosis and treatment monitoring.
      Jon Holmes in Andy Hill Appointed Chief Executive Officer of Michelson Diagnostics